



(51) International Patent Classification:

A61K 38/26 (2006.01) A61K 47/32 (2006.01)
A61K 9/00 (2006.01) A61K 47/38 (2006.01)
A61K 9/20 (2006.01) A61P 1/16 (2006.01)
A61K 47/12 (2006.01) A61P 3/10 (2006.01)
A61K 47/18 (2017.01) A61P 13/12 (2006.01)

(21) International Application Number:

PCT/US2024/019883

(22) International Filing Date:

14 March 2024 (14.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,512 15 March 2023 (15.03.2023) US

(71) Applicant: **VIKING THERAPEUTICS, INC.** [US/US];
9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US).

(72) Inventors: **LIAN, Brian**; c/o Viking Therapeutics, Inc.,
9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **BARKER, Geoffrey E.**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San

Diego, California 92121 (US). **BARNES, Maureen**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **YAGIZ, Kader**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **GONZALEZ, Jake**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US).

(74) Agent: **CHRISTENSEN, Michael R.**; KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS




FIG. 1

(57) Abstract: Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP/GLP-1 dual receptor agonists and uses thereof.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*